Current Issues of Pharmacy and Medical Sciences

Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)?

Curr Issues Pharm Med Sci., Vol. 30, No. 4, 207-210

Sebastian Blaj, Pompiliu Piso

Klinik für Allgemein- und Viszeralchirurgie, Krankenhaus Barmherzige Brüder Regensburg, Prüfeninger 86, 93049 Regensburg, Germany

DOI: https://doi.org/10.1515/cipms-2017-0040

Abstract

The gastric cancer with peritoneal metastases still represents a serious problem in the oncological surgery, whereas the peritoneal metastases arising from colorectal cancer can be successfully treated using a multimodal therapy concept consisting of systemic chemotherapy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The best survival rates in patients suffering from peritoneal metastases of gastric cancer have been reported by the ToGa trial, in patients with HER-2 positive expression who received standard chemotherapy and trastuzumab. Cytoreductive surgery and HIPEC are increasingly wining a place in the multimodal therapy of gastric cancer with peritoneal metastases, the criteria for such an aggressive therapy are strict and the operability needs to be previously assessed by laparoscopic exploration. Interesting new data are awaited from the German GASTRIPEC study and from the French GASTRICHIP study.

Full text


Keywords

peritoneal neoplasms, hyperthermia, induced, stomach neoplasms, cytoreduction surgical procedures, induction chemotherapy, laparoscopy

Calendar

November 2019

Mon Tue Wed Thu Fri Sat Sun
        01 02 03
04 05 06 07 08 09 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30